Date: 2013-07-08
Type of information: Grant
Company: Galapagos (Belgium)
Investors: Flemish agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €2.4 million
Funding type: grant
Planned used: The grant will be used to explore the potential application of a new compound series in disease models for psoriasis, both in preclinical systems as well as in a clinical setting.
Others: * On July 8, 2013, Galapagos has announced that it has been awarded a €2.4 million TGO (transformational medical research) grant from the Flemish agency for Innovation by Science and Technology (IWT) for psoriasis research and development. The goal of this 4-year project is to bring a novel mode of action compound into the clinic that might lead to a safe and effective treatment for patients suffering from psoriasis.
Galapagos has discovered a compound series which presents a novel mode of action in psoriasis. This 4-year IWT funded research program will explore the potential application of this compound series in disease models for psoriasis, both in preclinical systems as well as in a clinical setting. After the discovery phase, Galapagos will initiate clinical trials with this innovative, oral compound for psoriasis by using an adaptive trial design, with the aim of achieving an efficiency gain in development costs and timelines. In the clinic, pharmacodynamic assessments will be evaluated in healthy volunteers by mimicking inflammation characteristics in a Proof-of-Mechanism study. Galapagos will collaborate in this project with Professor Dr Jo Lambert at Ghent University.
Therapeutic area: Autoimmune diseases - Dermatological diseases
